Prostate Neoplasms
44
2
4
28
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
19 trials with published results (43%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
11.4%
5 terminated out of 44 trials
84.8%
-1.7% vs benchmark
7%
3 trials in Phase 3/4
68%
19 of 28 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 28 completed trials
Clinical Trials (44)
Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
Fusion Guided Focal Laser Ablation of Prostate Cancer
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
Study to Evaluate the Clinical Impact of a Laparoscopic Radical Prostatectomy Simulator
Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy
A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)
Novel Therapy Target in Metastatic Prostate Cancer
Effects of Music and Conversation in Prostate Biopsy
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
CyberKnife Radiosurgery for Organ-Confined Prostate Cancer: Homogenous Dose Distribution
CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry
A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases